Kidney Fibrosis Treatment Market Report 2025

The kidney fibrosis treatment market size has grown strongly in recent years. It will grow from $5.62 billion in 2024 to $6.06 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to growing research and development investments in fibrosis-targeting therapies, increasing government funding for kidney disease management initiatives, rising patient awareness of kidney transplantation and fibrosis treatment options, increasing healthcare infrastructure, and rising prevalence of aging populations.

The kidney fibrosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.21 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing prevalence of chronic kidney diseases, rising demand for advanced therapies for renal fibrosis management, growing awareness of early-stage kidney fibrosis detection, increasing adoption of personalized medicine in kidney disease treatment, and rising incidence of diabetes and hypertension. Major trends in forecast period includes technology advancements in early detection and diagnostic tools, advancements in gene therapy, technology integration in telemedicine and remote monitoring, advancements in stem cell therapies, and advancements in drug delivery systems.

The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden nephrology clinics by increasing costs of antifibrotic therapies sourced from Germany and Japan, exacerbating chronic kidney disease management expenses and elevating renal care burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of chronic kidney disease (CKD) is expected to drive the growth of the kidney fibrosis treatment market in the coming years. CKD is a progressive loss of kidney function, often caused by conditions such as diabetes or hypertension, which lead to the accumulation of waste products in the body. The increasing rates of diabetes, which damages kidney blood vessels and impairs their ability to filter waste, are a key factor contributing to the rise in CKD. Kidney fibrosis treatments target kidney tissue scarring, reduce inflammation, and slow the progression of kidney damage, ultimately helping to preserve kidney function. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that around 14% of U.S. adults, or approximately 35.5 million people, are living with chronic kidney disease. As a result, the growing prevalence of CKD is driving the expansion of the kidney fibrosis treatment market.

The increasing number of clinical trials is also expected to fuel the growth of the kidney fibrosis treatment market. Clinical trials are research studies conducted on humans to assess the safety, effectiveness, and potential side effects of medical treatments or interventions. The rising demand for personalized and innovative therapies, which require extensive testing to ensure safety and efficacy, is driving the increase in clinical trials. Kidney fibrosis treatments play a crucial role in these trials by offering a focused area for testing novel anti-fibrotic therapies, enabling researchers to evaluate the effectiveness of new drugs in slowing or even reversing kidney damage. For instance, in November 2023, the Association of the British Pharmaceutical Industry reported a 15% increase in annual recruitment to clinical trials in the UK, rising from 36,722 participants in 2021-22 to 42,088 in 2022-23. As clinical trials continue to grow, so too does the demand for kidney fibrosis treatments.

In May 2023, Chinook Therapeutics, a U.S.-based biotechnology company, partnered with Ionis Pharmaceuticals, another U.S.-based biotech firm, to develop a precision therapy for chronic kidney disease. This collaboration aims to create an antisense oligonucleotide therapy targeting the genetic causes of rare, severe forms of CKD, with the goal of improving patient outcomes and reducing the need for dialysis or kidney transplants. Ionis Pharmaceuticals is also developing therapies for kidney fibrosis, including IONIS-FB-LRx, a treatment for IgA nephropathy, further highlighting the push toward innovative treatments for CKD.

Major players in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kidney fibrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney fibrosis treatment market includes revenues earned by entities by providing services such as pharmacological treatment, diagnostic and monitoring services, and lifestyle and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The kidney fibrosis treatment market research report is one of a series of new reports that provides kidney fibrosis treatment market statistics, including the kidney fibrosis treatment industry's global market size, regional shares, competitors with the kidney fibrosis treatment market share, detailed kidney fibrosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kidney fibrosis treatment market. This kidney fibrosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Kidney fibrosis treatment refers to therapeutic approaches aimed at slowing, halting, or reversing the progression of fibrosis in the kidneys. Kidney fibrosis is the excessive buildup of extracellular matrix proteins, such as collagen, leading to scarring and a decline in kidney function, commonly associated with chronic kidney disease (CKD).

The primary treatment types for kidney fibrosis include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), pirfenidone, renin inhibitors, vasopeptidase inhibitors, and others. ACE inhibitors help lower blood pressure and reduce heart strain by blocking the enzyme that converts angiotensin I into angiotensin II. Diagnosis involves blood and urine tests, imaging scans, and kidney biopsies. These treatments are used for chronic kidney diseases, kidney cancer, and other related conditions. They are applied by various end-users, such as clinics, research centers, and hospitals.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.